Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
The state-of-the-art digital PETCT imaging system, highlights a significant advancement in the fight against cancer and detects other lesions offering patient centric services
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
Subscribe To Our Newsletter & Stay Updated